These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7356902)

  • 1. Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?
    Aitio ML; Vuorenmaa T
    Br J Clin Pharmacol; 1980 Feb; 9(2):149-52. PubMed ID: 7356902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of enzyme induction on the metabolism of disopyramide in man.
    Aitio ML; Mansury L; Tala E; Haataja M; Aitio A
    Br J Clin Pharmacol; 1981 Mar; 11(3):279-85. PubMed ID: 7213529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
    Aitio ML
    Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of disopyramide on left ventricular performance: the relationship of free and total concentrations of the drug and of its mono-N-dealkylated metabolite to noninvasive indices of function.
    Holt GW; Norris RL; Ravenscroft PJ; Bett JH; Dryburgh LG; Boyle CM
    J Cardiovasc Pharmacol; 1983; 5(1):51-4. PubMed ID: 6186859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Accumulation of a disopyramide metabolite in renal failure].
    Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions with the cardiac cholinergic system: effects of disopyramide and its mono-N-dealkylated metabolite.
    Boucher M; Chassaing C; Herbet A; Duchêne-Marullaz P
    Life Sci; 1992; 50(20):PL161-6. PubMed ID: 1579041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
    Toy W; Sasyniuk BI
    J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disopyramide concentrations in saliva.
    Aitio ML; Virtanen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide.
    Aitio ML
    Med J Aust; 1979 Nov; 2(10):550. PubMed ID: 530161
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the effects of quinidine, diphenylhydantoin and disopyramide on the auricular refractory period in the anesthetized dog].
    Duchêne-Marullaz P; Lapalus P; Lavarenne J; Combre A
    Arch Int Pharmacodyn Ther; 1974 Sep; 211(1):150-8. PubMed ID: 4460907
    [No Abstract]   [Full Text] [Related]  

  • 16. Accumulation of a disopyramide metabolite in renal failure.
    Inagaki Y; Amano I; Otsu T
    ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
    Haughey DB; Steinberg I; Lee MH
    J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal dialysis of disopyramide in healthy subjects.
    Arimori K; Kawano H; Nakano M
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):280-4. PubMed ID: 2737797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of altered disopyramide binding on its pharmacologic response in rabbits.
    Huang JD; Oie S
    J Pharmacol Exp Ther; 1982 Nov; 223(2):469-71. PubMed ID: 7131300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.